ABBOTT INDIA LIMITED

Luna Diabetes launches pivotal trial for Luna, its miniature automated insulin delivery system, designed to transform nighttime glucose management. The world's smallest patch pump delivers micro-doses of insulin during sleep, aiming to simplify onboarding and offer a unique algorithm for insulin pens. The trial, expected to complete in August 2025, aims to evaluate Luna's safety and efficacy in lowering blood sugar levels during sleep.

Study on 115 patients with AF, who underwent AFCA and AMD treatment, focusing on creating a digital twin of the LA by merging pre-ablation CT images with EAM data. The study evaluated electrophysiological changes under AMD treatment, assessed the effectiveness of AMD in patients, and correlated the effects of virtual and clinical AMD to predict the probability of maintaining sinus rhythm 1 year after AMD treatment.

Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.

Global Personalized Medicines Market to grow from USD 588.31 Million in 2023 to USD 1,007.05 Million by 2031, driven by advancements in genetic technology and rising prevalence of rare diseases. North America leads in demand due to high healthcare expenditure, while Asia-Pacific shows the fastest growth. Market segments include diagnostics, genetic testing, and end-uses like hospitals and diagnostic centers. Key players are investing in R&D and collaborations, and insurance coverage and healthcare budgets are expanding.

Horizon Surgical Systems, a micro-robotics company, closed a $30 million Series A round to advance its AI-enabled Polaris platform for ophthalmologic procedures. The funding will support in-human studies and team expansion, aiming to enhance surgical precision and accessibility. ExSight Ventures and a major corporate investor led the financing, with key figures joining Horizon's board.

Most medical devices, including implants, don't face rigorous FDA safety standards, leading to avoidable harm and recalls. A study found 157 heart devices with class I recalls from 2013-2022, with only 20% tested clinically. Critics argue for more science in FDA approval processes, noting public pressure for faster approvals may compromise safety.

iCardio.ai received FDA 510(k) clearance for its AI software for echocardiography interpretation, aiming for comprehensive imaging workflow and autonomous preliminary reporting. The company develops machine learning algorithms for ultrasound applications, focusing on transthoracic echo. iCardio.ai has started commercial operations and received FDA clearance for EchoMeasure, its first software, which supports automated echocardiographic interpretation. The clearance will support future algorithms, including those for structural heart disease detection. Additionally, the company's algorithms for valvular heart disease detection have attracted interest from health systems and prosthetic valve manufacturers. iCardio.ai collaborated with Abbott to develop AI applications for imaging devices and joined the Cedars-Sinai Accelerator program. The company also partnered with SAR Mediq to accelerate AI in cloud PACS and cardiology healthcare.

Abbott partners with the Big Ten Conference for 'We Give Blood Drive' to address national blood shortages, offering $1 million to the school with the most donations. Abbott also completed enrollment for its VOLT-AF IDE study and launched Lingo, a real-time glucose monitoring system available without a prescription in the U.S.

Abbott received FDA clearance for its advanced cardiac mapping technology, crucial for ongoing pulsed field ablation (PFA) studies aimed at improving atrial fibrillation (AF) treatment. This development promises more precise interventions and better patient outcomes, potentially transforming AF treatment with non-thermal energy ablation.

Diamyd Medical presents precision medicine data at ISPAD and IDS conferences, highlighting potential to delay Type 1 Diabetes progression. Key findings include Diamyd®'s ability to delay disease in children with HLA DR3-DQ2, and the necessity of a precision medicine approach based on HLA genotype variations.